Clinical trials: Disorder, Mood
Schizophrenia, Schizo Affective Disorder
The Efficacy of Neural Stimulation in Individuals With Schizophrenia
The purpose of this study is to understand the relationship between psychotic symptoms and social functioning in individuals with schizophrenia spectrum disorders.
- Trial name
- NCT05746494
- Testing
- tDCS
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The University of Texas at Dallas
Major Depressive Disorder
Transcranial Laser Therapy for Major Depressive Disorder
The purpose of this study is to see if using Transcranial LED Therapy (TLT) using the PhotoMedex's Omnilux NEw-U LED helps improve symptoms of major depressive disorder (MDD).
- Trial name
- ELATED (NCT01538199)
- Testing
- Near-infrared radiation via Transcranial LED Therapy
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Paolo Cassano
Schizophrenia, Schizo Affective Disorder
Brain Stimulation and Cognitive Training - Efficacy
People with serious mental illness often experience difficulties with thinking skills like memory. These difficulties can make it harder to perform day-to-day activities.
- Conditions
- Schizophrenia, Schizo Affective Disorder, Bipolar Disorder
- Trial name
- NCT05111548
- Testing
- tDCS (Active), BrainHQ, tDCS (Inactive)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Michigan
Hearing Loss, Depression
Treating Hearing Loss to Improve Mood and Cognition in Older Adults
Age-related hearing loss (ARHL) is the third most common health condition affecting older adults after heart disease and arthritis and is the fifth leading cause of years lived with disability worldwide.
- Trial name
- NCT03321006
- Testing
- Phonak Audeo B-R 90 hearing aid device (Active), Duloxetine or escitalopram
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- New York State Psychiatric Institute
Depressive Disorder, Major, Anhedonia
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with…
- Trial name
- VENTURA-1 (NCT05455684)
- Testing
- Aticaprant
- Where
- 120 sites in United States, Argentina and 11 more
- Volunteers
- 513 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)
This study will evaluate the efficacy, safety, and tolerability of adjunctive ALKS 5461 in adults who have treatment refractory MDD.
- Trial name
- NCT03188185
- Testing
- ALKS 5461
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 278 people
- Sponsor
- Alkermes, Inc.
Treatment-resistant Depression
A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) subjects from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine…
- Trial name
- TRANSFORM-2 (NCT02418585)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 48 sites in United States, Czechia and 3 more
- Volunteers
- 236 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)
This study will evaluate the efficacy, safety, and tolerability of rapastinel 450 mg compared to placebo adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD) who have a partial response to…
- Trial name
- NCT02932943
- Testing
- Rapastinel
- Where
- 31 sites in United States
- Volunteers
- 465 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Refractory Major Depressive Disorder
A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)
This study will assess the long-term safety and tolerability of ALKS 5461 as an adjunctive treatment for refractory MDD.
- Trial name
- NCT03610048
- Testing
- ALKS 5461
- Where
- 34 sites in United States, Australia and 1 more
- Volunteers
- 175 people
- Sponsor
- Alkermes, Inc.
Post Traumatic Stress Disorder, Major Depressive Disorder
Accelerated TMS to a Novel Brain Target in MDD and PTSD
This is a Clinical Trial designed to evaluate novel transcranial magnetic stimulation (TMS) methods for treating depression/PTSD. TMS is an FDA-approved procedure for treatment-resistant depression.
- Trial name
- NCT03114891
- Testing
- Transcranial Magnetic Stimulation (TMS), Task, fMRI-guided TMS target
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Pennsylvania
Generalized Anxiety Disorder
Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in adults with generalized anxiety disorder.
- Trial name
- NCT00730691
- Testing
- Vortioxetine, Duloxetine
- Where
- 66 sites in United States
- Volunteers
- 781 people
- Sponsor
- Takeda
Depression, Unipolar
Ketamine + Mindfulness for Depression
In this project, the investigators will administer a single infusion of IV ketamine to depressed patients and randomize the patients to receive either a) usual/typical infusion conditions or b) mindfulness training and exercises…
- Trial name
- NCT05168735
- Testing
- Intravenous Ketamine, Brief Mindfulness Exercises, Academic Exercises
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Rebecca Price
Major Depressive Disorder
Neurobiological Bases of Placebo Response in Major Depressive Disorder
We are doing this research study to find out if people who get better while taking a specific kind of antidepressant medication (a selective serotonin reuptake inhibitor, or SSRI) and people who get better while taking placebo…
- Trial name
- NCT01787240
- Testing
- Escitalopram 10mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Bipolar Disorder
Lurasidone Extended Use Study
This is an open-label continuation study designed to monitor the safety, tolerability and effectiveness of lurasidone in subjects who have completed participation in a lurasidone extension study (NCT00868959 and NCT01566162) and…
- Trial name
- NCT01485640
- Testing
- Lurasidone
- Where
- 46 sites in Canada, Colombia and 10 more
- Volunteers
- 162 people
- Sponsor
- Sumitomo Pharma America, Inc.
Major Depressive Disorder, MDD
Virtual Reality Behavioral Activation: An Intervention for Major Depressive Disorder
The primary purpose of this study is to test the safety and feasibility of virtual reality (VR) technology in the use of behavioral activation (BA) as a treatment for major depressive disorder (MDD).
- Conditions
- Major Depressive Disorder, MDD, Depression
- Trial name
- NCT04268316
- Testing
- Virtual Reality Behavioral Activation, Behavioral Activation in real-life
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Bipolar Disorder
Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder
The purpose of this study is to determine if ziprasidone is safe and effective for the treatment of children and adolescents (ages 10-17) with bipolar I disorder (manic or mixed).
- Trial name
- NCT02075047
- Testing
- ziprasidone oral capsules
- Where
- 50 sites in United States, Ukraine
- Volunteers
- 171 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Major Depressive Disorder
Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)
This is a phase 3, flexible-dose, open-label, multi-center study. The subjects who complete the week 8 visit in the prior double-blind study (B2411263) will be eligible to participate in this study.
- Trial name
- NCT01485887
- Testing
- Venlafaxine ER
- Where
- 25 sites in Japan
- Volunteers
- 50 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Unipolar Depression, Bipolar Depression
Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression
The study aims to compare outcomes of Electroconvulsive Therapy (ECT) using ketamine versus methohexital anesthesia in depressed patients.
- Trial name
- NCT01881763
- Testing
- Ketamine, Methohexital
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Northwell Health
Major Depressive Disorder
Open Label Extension for GLYX13-C-202, NCT01684163
Examine the safety of long term repeat exposure to GLYX-13 in subjects who participated in GLYX13-C-202.
- Trial name
- NCT02192099
- Testing
- Rapastinel (225 mg/450 mg IV administration)
- Where
- 10 sites in United States
- Volunteers
- 61 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Schizophrenia, Schizo-affective Disorder
Illness Management and Recovery for Veterans With Severe Mental Illness
The President's New Freedom Commission on Mental Health has called for a transformation of the mental health system to partner with consumers of those services in delivering effective interventions focused on recovery, and the…
- Trial name
- NCT00515671
- Testing
- Illness Management and Recovery, Problem Solving
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- VA Office of Research and Development
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.